Company profile CLDX

Celldex Therapeutics Inc.
Description of the company is not available.
Quarter analysis & expected interestLast update: October 09 2023 06:01:24.

After 92 days of this quarter the interest is at 316.0. Based on that we can calculate that during remaining 0 days it will total up to 316.0.
Celldex Therapeutics expected interest is significantly higher compared to previous quarter (+110.7%) and same quarter last year (+206.8%).

YearQ1Q2Q3Q4
2018 - - - 174
2019 278
59.8% QoQ
167
-39.9% QoQ
150
-10.2% QoQ
205
17.8% YoY 36.7% QoQ
2020 39
-86.0% YoY -81.0% QoQ
276
65.3% YoY 607.7% QoQ
307
104.7% YoY 11.2% QoQ
199
-2.9% YoY -35.2% QoQ
2021 200
412.8% YoY 0.5% QoQ
91
-67.0% YoY -54.5% QoQ
166
-45.9% YoY 82.4% QoQ
190
-4.5% YoY 14.5% QoQ
2022 166
-17.0% YoY -12.6% QoQ
104
14.3% YoY -37.3% QoQ
103
-38.0% YoY -1.0% QoQ
163
-14.2% YoY 58.3% QoQ
2023 195
17.5% YoY 19.6% QoQ
150
44.2% YoY -23.1% QoQ
316
206.8% YoY 110.7% QoQ
37
-77.3% YoY -88.3% QoQ
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Celldex Therapeutics search interestLast update: October 09 2023 06:01:23.
Correlation coefficient between keyword and revenue is -0.25
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: October 09 2023 06:01:24.

The average 5 years interest of Celldex Therapeutics was 14.14 per week.
The last year interest of Celldex Therapeutics compared to the last 5 years has changed by 17.11%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by 11.97%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Celldex Therapeutics clinical trials to provide analysis

Correlation between past revenue and Celldex Therapeutics clinical trials search interest

There is not enough data for Celldex Therapeutics clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Celldex Therapeutics clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Celldex Therapeutics antibody therapies to provide analysis

Correlation between past revenue and Celldex Therapeutics antibody therapies search interest

There is not enough data for Celldex Therapeutics antibody therapies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Celldex Therapeutics antibody therapies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Celldex Therapeutics cancer treatments to provide analysis

Correlation between past revenue and Celldex Therapeutics cancer treatments search interest

There is not enough data for Celldex Therapeutics cancer treatments to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Celldex Therapeutics cancer treatments to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Celldex Therapeutics CDX-0159 to provide analysis

Correlation between past revenue and Celldex Therapeutics CDX-0159 search interest

There is not enough data for Celldex Therapeutics CDX-0159 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Celldex Therapeutics CDX-0159 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Celldex Therapeutics CDX-1140 to provide analysis

Correlation between past revenue and Celldex Therapeutics CDX-1140 search interest

There is not enough data for Celldex Therapeutics CDX-1140 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Celldex Therapeutics CDX-1140 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Celldex Therapeutics CDX-527 to provide analysis

Correlation between past revenue and Celldex Therapeutics CDX-527 search interest

There is not enough data for Celldex Therapeutics CDX-527 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Celldex Therapeutics CDX-527 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Celldex Therapeutics stock price to provide analysis

Correlation between past revenue and Celldex Therapeutics stock price search interest

There is not enough data for Celldex Therapeutics stock price to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Celldex Therapeutics stock price to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: October 09 2023 06:01:55.

After 92 days of this quarter the interest is at 64.0. Based on that we can calculate that during remaining 0 days it will total up to 64.0.
Celldex Therapeutics news expected interest is significantly higher compared to previous quarter (+137.0%) but similar to same quarter last year.

YearQ1Q2Q3Q4
2018 - - - 246
2019 33
-86.6% QoQ
100
203.0% QoQ
99
-1.0% QoQ
71
-71.1% YoY -28.3% QoQ
2020 28
-15.2% YoY -60.6% QoQ
97
-3.0% YoY 246.4% QoQ
106
7.1% YoY 9.3% QoQ
133
87.3% YoY 25.5% QoQ
2021 161
475.0% YoY 21.1% QoQ
0
-100.0% YoY -100.0% QoQ
162
52.8% YoY inf% QoQ
64
-51.9% YoY -60.5% QoQ
2022 211
31.1% YoY 229.7% QoQ
104
inf% YoY -50.7% QoQ
64
-60.5% YoY -38.5% QoQ
0
-100.0% YoY -100.0% QoQ
2023 112
-46.9% YoY inf% QoQ
27
-74.0% YoY -75.9% QoQ
64
0.0% YoY 137.0% QoQ
0
0.0% YoY -100.0% QoQ
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Celldex Therapeutics news search interestLast update: October 09 2023 06:01:54.
Correlation coefficient between keyword and revenue is -0.23
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: October 09 2023 06:01:55.

The average 5 years interest of Celldex Therapeutics news was 7.24 per week.
The last year interest of Celldex Therapeutics news compared to the last 5 years has changed by -46.13%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -57.56%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Celldex Therapeutics -stock -company to provide analysis

Correlation between past revenue and Celldex Therapeutics -stock -company search interest

There is not enough data for Celldex Therapeutics -stock -company to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Celldex Therapeutics -stock -company to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for CLDX
Earnings date: 2024-03-07 After close
Company name: Celldex Therapeutics Inc.
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-13T13:26:56Z

Analyst Upgrades
Wells Fargo Maintains Overweight on Celldex Therapeutics, Raises Price Target to $54

2026-05-08T14:42:54Z

Analyst Upgrades
Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $48

2026-05-07T20:01:00Z

GlobeNewswire
Celldex Reports First Quarter Financial Results and Provides Corporate Update

2026-04-20T13:11:46Z

Analyst Upgrades
Barclays Upgrades Celldex Therapeutics to Overweight, Raises Price Target to $45

2026-04-13T20:01:00Z

GlobeNewswire
Celldex to Present at Upcoming Investor Conference

2026-04-06T14:53:52Z

GlobeNewswire
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

2026-04-02T01:48:19Z

GlobeNewswire
Celldex Announces Pricing of $300 Million Public Offering of Common Stock

2026-04-01T20:01:00Z

GlobeNewswire
Celldex Announces Proposed Public Offering of Common Stock

2026-03-27T14:30:00Z

GlobeNewswire
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026

2026-03-02T17:11:07Z

Analyst Upgrades
Goldman Sachs Maintains Neutral on Celldex Therapeutics, Raises Price Target to $34

2026-03-01T14:45:00Z

GlobeNewswire
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

2026-02-27T19:45:00Z

GlobeNewswire
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

2026-02-26T14:19:40Z

Analyst Upgrades
Stifel Reiterates Buy on Celldex Therapeutics, Raises Price Target to $68

2026-02-25T21:01:00Z

GlobeNewswire
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

2026-02-25T12:01:00Z

GlobeNewswire
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria